🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Artificial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility Study

RecruitingNAAges 18 Years - anyAllNiguarda Hospital
NCT07664748 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Heart failure is a serious condition and a major reason why older adults are admitted to the hospital. Even after going home, many patients struggle to get the follow-up care they need, leading to high rates of return to the hospital. While remote monitoring technology exists, it is often difficult to use, expensive, or hard for doctors to interpret. Recent research suggests that changes in a person's voice and speech can be early warning signs of worsening heart failure, but we need to test if this can work reliably in a home setting.This study tests a new, user-friendly platform called AVATAR-SC. This system uses a a computer-generated character to interact with patients. By analyzing short voice clips and simple health questionnaires provided by the patient, the system aims to make home monitoring easier and more effective. The study will involve 60 participants divided into two g

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria * Age ≥ 18 years * Diagnosis of heart failure (NYHA Class II-IV), according to the Diagnosis Related Group (DRG) classification. * Recent discharge following acute heart failure (AHF) or ongoing treatment with Levosimendan in a Day Hospital setting. * Provision of signed informed consent in Italian. * Currently receiving Guideline-Directed Medical Therapy (GDMT) for heart failure Exclusion Criteria: * Inability or incapacity to provide informed consent. * Cognitive impairment severe enough to prevent interaction with the avatar and compromise the reliability of the collected data. * Significant phonation disorders (e.g., results of previous otorhinolaryngological surgery or post-traumatic outcomes). * Inability to manage a compatible device or the device provided by the study for interaction with the AVATAR-SC platform. * Life expectancy of less than 6 months due to concurrent comorbidities. * Technological or language barriers.
💊

What it tests

  • AVATAR-SC
  • Levosimendan
📍

Where

1 site
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy